First Light Asset Management Reduces Stake in Vera Therapeutics

Biotech firm's shares sold by investment firm in third quarter

Mar. 16, 2026 at 10:05am

Got story updates? Submit your updates here. ›

First Light Asset Management LLC decreased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 9.9% in the 3rd quarter, according to the company's recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 507,097 shares of the company's stock after selling 55,884 shares during the period.

Why it matters

Vera Therapeutics is a clinical-stage biotech company focused on developing novel immunotherapies for autoimmune and inflammatory diseases. The reduction in First Light Asset Management's stake could signal a shift in investor sentiment or portfolio rebalancing, which could impact the company's stock price and future funding.

The details

First Light Asset Management LLC sold 55,884 shares of Vera Therapeutics in the third quarter, reducing its total holdings to 507,097 shares. The firm's stake in Vera Therapeutics now represents approximately 0.79% of its portfolio. Other institutional investors, including Bank of America Corp DE, Braidwell LP, and Deerfield Management Company L.P., have also adjusted their positions in Vera Therapeutics during the same period.

  • First Light Asset Management LLC decreased its holdings in Vera Therapeutics in the 3rd quarter of 2026.

The players

First Light Asset Management LLC

An investment management firm that decreased its stake in Vera Therapeutics by 9.9% in the third quarter.

Vera Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing novel immunotherapies for autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in First Light Asset Management's stake in Vera Therapeutics could signal a shift in investor sentiment or portfolio rebalancing, which could impact the company's stock price and future funding. However, the company's focus on developing innovative immunotherapies for autoimmune and inflammatory diseases continues to attract interest from other institutional investors.